Mario Balsa

Sesión plenaria - II congreso de la @FundacionTTCC Proyecto REDESIGN: alt. moleculares al diagnóstico en SGC 🧬 implicaciones pronósticas 📈 y posibles 🎯 terapéuticas Gracias al @ttccgroup y a los investigadores, en especial al Dr. @OlivaM_Onc @OncoReporte @OncoAlert @_SEOM

💥 Another #OncoAlert WEEKLY RoundUp! 🔥 oncoalert.m-pages.com/nhMpwe/oncoale… From TALAPRO2 & Geriatric Assessments to ACCORD in #Cholangiocarcinoma & Microbiome modulation—don’t miss what’s shaping the week in #Oncology 🧬 👀 Catch the full rundown 👇 @OncoAlert

🚨 Another hot week on @OncoAlert! oncoalert.m-pages.com/nhMpwe/oncoale… ▪️ From ctDNA to FLAURA2, INTERCEPT-TT, surgery vs RT, and EGFRm personalization… 🎯 Don’t just catch up…stay ahead! Let’s round up what really matters in oncology 💥

🚨 New comprehensive review on NK cell therapy in #HCC, emerging as a potent immunotherapeutic tool: pubmed.ncbi.nlm.nih.gov/40668523/ 🔛 From cytokines to checkpoint inhibitors, the strategies are… naturally killing it 💥 @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM @GrupoTTD

🚨 New Nature Reviews Clin Oncol: MET as a therapeutic target in solid tumors 🧬 MET needs METiculous targeting—new agents, new hope! 💥 nature.com/articles/s4157… ▪️ METex14 = actionable oncogenic driver (esp. in NSCLC) ▪️ MET alterations: mutations, amplifications, fusions,…

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) buff.ly/UrXfLEu In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus…

Out in one of our partner Journals @CACancerJournal Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management buff.ly/vv1ol7z The discovery of EGFR 🧬 mutations has transformed the treatment of…

🧬 New review on miR-184 in #HCC link.springer.com/article/10.100… This miRNA plays a dual role—as oncogene or tumor suppressor—depending on target context. It impacts key pathways (Wnt/β-catenin, JAK2/STAT3), and interacts with multiple circRNAs & lncRNAs. 🎯 A promising biomarker…

Happy to share initial report on temporal change of CLDN18.2 after chemo + zolbetuximab: ~50% showed decreased expression (<75%+ cells) on PD, but 75% retained ≥25% expression—supporting potential for other CLDN-targeted tx like ADCs @ESMO_Open @myESMO   sciencedirect.com/science/articl…

The @OncoAlert JOURNAL CLUB! @VJOncology STAMPEDE update in #ProstateCancer: Adding metformin to ADT in non-diabetic mHSPC didn’t improve OS ❌ ▪️Did help with metabolic side effects ▪️GI AEs mostly mild 📉 Not a game-changer, but a reminder: not every STAMPEDE shakes the…

Ovarian Cancer jamanetwork.com/journals/jama/…

#PallOnc RCT in @JCO_ASCO App 📲for #caregivers of #HSCT 🩸pts: ⬆️ #QoL 😄 ⬇️ caregiving #burden 🏋️‍♂️ depression and PTSD 😫 Need to increase impact and scale #supponc 🔗: ascopubs.org/doi/10.1200/JC… @Areejmd @TamrynGray @PallOncCoP @MazieTsangMD @DarcyBurbage @Chaosdyna…

💥New review on surveillance after thymic epithelial tumors (TETs) med.amegroups.org/article/view/1… ▪️TETs can recur late, especially thymomas ▪️Recurrences often intrathoracic, asymptomatic 🔍 CT-based follow-up widely recommended 📉 No prospective data; 5 guidelines support >10y…

📘 Narrative review on thymic epithelial tumors (TETs): does size matter? med.amegroups.org/article/view/1… ▪️Tumor size included in 9th TNM edition (T1a ≤5cm / T1b >5cm) 🔎 35 studies reviewed 💥Larger size = ↑ recurrence, ↑ invasion, ↓ resection rates 🧬 Prognostic value clearest in…

🔥Can we predict relapse in colon cancer before surgery❓Together with @HMar_research and @QuibimBiomarker, we built an AI-radiomics model that identifies high-risk patients from pre-op CT scans. 📌Published in @ESMO_Open 🔗sciencedirect.com/science/articl…

🚨 Patterns of recurrence in esophageal adenocarcinoma comparing FLOT vs CROSS— ESOPEC trial update 💥 ascopubs.org/doi/10.1200/JC… ▪️Locoregional recurrence (3-yr CI): FLOT 20.2% vs CROSS 17.4% (NS) ▪️Distant recurrence (3-yr CI): FLOT 31.5% vs CROSS 47.2% (p=.002) CROSS-ing paths,…

🚨 New in @NatRevUrol! A top-tier review on non-clear cell RCC: nature.com/articles/s4158… ▪️20–30% of RCC cases 🧬 Key drivers: MET, mTOR, ALK, SMARCB1 ▪️Subtype-specific microenvironments 💊 Mixed responses to TKIs, ICI, chemo Precision lies in decoding the “unclear” nature of…

🚨 Fresh in @JCO_ASCO! ENGOT-OV60/RAMP 201: avutometinib (MEK clamp) ± defactinib (FAK inhibitor) in recurrent LGSOC after ≥1 line of platinum ascopubs.org/doi/10.1200/JC… 🎯 ORR 31% overall | 44% in KRAS-mut vs 17% WT 🎯 PFS 22.0m (KRAS-mut), 12.8m (WT) 🕒 DOR 31.1m ✅ Well…

🚀 Final OS results from the phase III TALAPRO-2 trial now published @TheLancet! Talazoparib + enzalutamide improved OS and rPFS in HRR-deficient mCRPC vs enzalutamide alone—especially in BRCA1/2-altered tumors. 💥 Double the action, double the benefit? TALAPROved!

New editorial in @MASCC_JSCC @NaomiTakemura discusses as #SurvOnc ⬆️ many face complex challenges Adapting #TreatableTraits model - a personalized approach: 👨‍⚕️clinical 🏋️‍♂️physical 🏃lifestyle, and ⛪️psychospiritual needs 🔗: link.springer.com/article/10.100… @DrNicolasHart…

💉1L biologics in early-onset CRC @JCOOA_ASCO 🚨⁉️No benefit of EGFRi in left-sided RAS/RAF wt tumors, in contrast to average-onset 👉ascopubs.org/doi/pdfdirect/… @ASCO @CathyEngMD @OncoAlert @realbowtiedoc #cancer #oncology #MedX #colorectal